# Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

Study · id `cardio:ct-nct01983735` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01983735](<https://clinicaltrials.gov/study/NCT01983735>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01983735

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01983735. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2014-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01983735, source copy `cardio:ctgov-nct01983735-2013-11-14`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT01983735, source copy `cardio:ctgov-nct01983735-2013-11-14`, retrieved 2026-10-26)
- Primary completion: 2014-08 (anticipated) (ClinicalTrials.gov record NCT01983735, source copy `cardio:ctgov-nct01983735-2013-11-14`, retrieved 2026-10-26)
- Completion: 2014-08 (anticipated) (ClinicalTrials.gov record NCT01983735, source copy `cardio:ctgov-nct01983735-2013-11-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01983735, source copy `cardio:ctgov-nct01983735-2013-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01983735-2013-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
- Condition: Hypertension
- Intervention (Drug): TELMINUVO Tab. (80/2.5mg)
- Intervention (Drug): TELMINUVO Tab. (80/5mg)
- Intervention (Drug): S-amlodipine 2.5mg
- Intervention (Drug): S-amlodipine 5mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: f787ad7a1b127e056f131ace175ec3895c16f418ff56d8848b19c4214e46e1be
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
